Saba Ghaffary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Saba Ghaffary has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Parvin Sarbakhsh
Tabriz University of Medical Sciences
6 shared publicationsAbbas Salehiomran
Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
3 shared publicationsAliakbar Movassaghpour Akbari
Tabriz University of Medical Sciences
3 shared publicationsArash Jalali
Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications- Azita Hajhossein Talasaz
Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Elnaz Shaseb
Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications
Latest Publications
- 15 December 2025
- Published byĀ SAGE PublicationsĀ inĀ Journal of Oncology Pharmacy Practice
- Vol.Ā 32 Ā (6) , 1153-1167
Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis
Introduction: Taxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC. Methods: A comprehensive data search was performed in PubMed, Web of Science, and Scopus up to August 2024. The studies that compare neuropathy in taxane agents were systematically reviewed. A network meta-analysis was carried out based on a Bayesian framework to evaluate the incidence of peripheral neuropathy in taxanes compared to paclitaxel, as reference comparator. The Surface Under the Cumulative Ranking Curve (SUCRA) was used to rank taxanes based on their neuropathy. Results: A total of 27 studies with 12101 patients were included. When compared with paclitaxel, nab-paclitaxel was associated with a significantly higher incidence of peripheral neuropathy (OR: 1.74, CrI: 1.22ā2.48). Docetaxel (OR: 0.626, CrI: 0.441ā0.881) and cabazitaxel (OR: 0.158, CrI: 0.0664ā0.375) demonstrated a significantly lower incidence of peripheral neuropathy compared to paclitaxel. Liposomal paclitaxel and PICN lack significant difference compared to paclitaxel. Our analysis provided the order for peripheral neuropathy (from lowest to highest) as follows: cabazitaxel, docetaxel, liposomal paclitaxel, paclitaxel, PICN, nab-paclitaxel. Conclusions: Nab-paclitaxel is associated with a significantly higher incidence of peripheral neuropathy compared to paclitaxel in females with BC. Docetaxel and cabazitaxel are linked with less peripheral neuropathy compared with paclitaxel in this population. No significant differences were observed in liposomal paclitaxel and PICN compared to paclitaxel.
- 15 December 2025
- Published byĀ SAGE PublicationsĀ inĀ Journal of Oncology Pharmacy Practice
- Vol.Ā 32 Ā (6) , 1153-1167
Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis
Introduction: Taxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC. Methods: A comprehensive data search was performed in PubMed, Web of Science, and Scopus up to August 2024. The studies that compare neuropathy in taxane agents were systematically reviewed. A network meta-analysis was carried out based on a Bayesian framework to evaluate the incidence of peripheral neuropathy in taxanes compared to paclitaxel, as reference comparator. The Surface Under the Cumulative Ranking Curve (SUCRA) was used to rank taxanes based on their neuropathy. Results: A total of 27 studies with 12101 patients were included. When compared with paclitaxel, nab-paclitaxel was associated with a significantly higher incidence of peripheral neuropathy (OR: 1.74, CrI: 1.22ā2.48). Docetaxel (OR: 0.626, CrI: 0.441ā0.881) and cabazitaxel (OR: 0.158, CrI: 0.0664ā0.375) demonstrated a significantly lower incidence of peripheral neuropathy compared to paclitaxel. Liposomal paclitaxel and PICN lack significant difference compared to paclitaxel. Our analysis provided the order for peripheral neuropathy (from lowest to highest) as follows: cabazitaxel, docetaxel, liposomal paclitaxel, paclitaxel, PICN, nab-paclitaxel. Conclusions: Nab-paclitaxel is associated with a significantly higher incidence of peripheral neuropathy compared to paclitaxel in females with BC. Docetaxel and cabazitaxel are linked with less peripheral neuropathy compared with paclitaxel in this population. No significant differences were observed in liposomal paclitaxel and PICN compared to paclitaxel.
- 19 December 2023
- Published byĀ Springer NatureĀ inĀ Supportive Care in Cancer
- Vol.Ā 32 Ā (1) , 1-9
Comparison of global decolonization efficacy with mupirocin nasal drop and chlorhexidine mouthwash in acute leukemia patients: randomized clinical trial
Purpose Neutropenic fever remains a major complication in acute leukemia. Decolonization is assumed as a promising intervention for eradicating causative agents of infection. Methods In this randomized clinical trial, 96 patients with acute leukemia were assigned randomly to mupirocin nasal drop 2% (n = 32), chlorhexidine mouthwash 0.2% (n = 33), and control group (n = 31). In control group, patients did not receive any medication for decolonization. All patients received treatment for 5 days (2 days prior to chemotherapy until 3 days after chemotherapy). Pharynx and nasal swabs were taken prior to the intervention and at the end of decolonization period in all groups. Antibiotic susceptibility testing was performed by the disc diffusion method in order to identify bacterial isolates. Results Bacterial recovery of both nasal and pharynx swabs was observed after global decolonization with mupirocin nasal drop. Decolonization with mupirocin significantly eradicated Coagulase-negative staphylococci (CONS) in both nasal and pharynx swabs (p-value = 0.000). Moreover, mupirocin decreased Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) species. Chlorhexidine mouthwash significantly eradicated CONS in pharynx swabs (p-value = 0.000). In addition, both decolonization strategies decreased both antibiotic use and frequency of fever in leukemic patients. Conclusion Global decolonization with mupirocin nasal drop not only eradicates both nasal and pharynx microorganisms, but also reduces antibiotic requirement and frequency of fever in patients with acute leukemia. The protocol of the present study was approved on December 2016 (registry number: IRCT20160310026998N6).
- 19 December 2023
- Published byĀ Springer NatureĀ inĀ Supportive Care in Cancer
- Vol.Ā 32 Ā (1) , 1-9
Comparison of global decolonization efficacy with mupirocin nasal drop and chlorhexidine mouthwash in acute leukemia patients: randomized clinical trial
Purpose Neutropenic fever remains a major complication in acute leukemia. Decolonization is assumed as a promising intervention for eradicating causative agents of infection. Methods In this randomized clinical trial, 96 patients with acute leukemia were assigned randomly to mupirocin nasal drop 2% (n = 32), chlorhexidine mouthwash 0.2% (n = 33), and control group (n = 31). In control group, patients did not receive any medication for decolonization. All patients received treatment for 5 days (2 days prior to chemotherapy until 3 days after chemotherapy). Pharynx and nasal swabs were taken prior to the intervention and at the end of decolonization period in all groups. Antibiotic susceptibility testing was performed by the disc diffusion method in order to identify bacterial isolates. Results Bacterial recovery of both nasal and pharynx swabs was observed after global decolonization with mupirocin nasal drop. Decolonization with mupirocin significantly eradicated Coagulase-negative staphylococci (CONS) in both nasal and pharynx swabs (p-value = 0.000). Moreover, mupirocin decreased Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) species. Chlorhexidine mouthwash significantly eradicated CONS in pharynx swabs (p-value = 0.000). In addition, both decolonization strategies decreased both antibiotic use and frequency of fever in leukemic patients. Conclusion Global decolonization with mupirocin nasal drop not only eradicates both nasal and pharynx microorganisms, but also reduces antibiotic requirement and frequency of fever in patients with acute leukemia. The protocol of the present study was approved on December 2016 (registry number: IRCT20160310026998N6).
- 20 July 2023
- Published byĀ SAGE PublicationsĀ inĀ Journal of Oncology Pharmacy Practice
- Vol.Ā 29 Ā (8) , 2023-2026
Delayed presentation of vincristine extravasation
Introduction: Vincristine is a vesicant chemotherapeutic agent which may leak from the vessel at the infusion site to the perivascular tissue and cause extravasation. Extravasation, a severe complication of chemotherapeutic drugs, can result in tissue necrosis that is considered an oncological emergency. Case report: We aimed to report a case of a 29-year-old woman with ALL-B cell (Acute lymphoblastic leukemia) on maintenance chemotherapy regimen including vincristine, methotrexate, prednisolone, and 6-mercaptopurine (POMP). 48 h after administering intravenous vincristine, the patient experienced burning, pain and tenderness at the injection site (left hand ā cubital cavity). Management & outcome: 7 days after the onset of symptoms, the patient was hospitalized with a large brown lesion at the site. She was prescribed betamethasone cream, DSMO (Dimethyl sulfoxide) solution, and oral levofloxacin on his second day after admission. The lesion was completely improved 10 days after initiation of therapy and there were no serious problems. Discussion: Due to the ineffectiveness of antidote therapy for the management of delayed extravasation of vincristine and beneficial effect of our clinical approach, it could consider for the management of similar cases with delayed extravasation following vincristine administration.
- 20 July 2023
- Published byĀ SAGE PublicationsĀ inĀ Journal of Oncology Pharmacy Practice
- Vol.Ā 29 Ā (8) , 2023-2026
Delayed presentation of vincristine extravasation
Introduction: Vincristine is a vesicant chemotherapeutic agent which may leak from the vessel at the infusion site to the perivascular tissue and cause extravasation. Extravasation, a severe complication of chemotherapeutic drugs, can result in tissue necrosis that is considered an oncological emergency. Case report: We aimed to report a case of a 29-year-old woman with ALL-B cell (Acute lymphoblastic leukemia) on maintenance chemotherapy regimen including vincristine, methotrexate, prednisolone, and 6-mercaptopurine (POMP). 48 h after administering intravenous vincristine, the patient experienced burning, pain and tenderness at the injection site (left hand ā cubital cavity). Management & outcome: 7 days after the onset of symptoms, the patient was hospitalized with a large brown lesion at the site. She was prescribed betamethasone cream, DSMO (Dimethyl sulfoxide) solution, and oral levofloxacin on his second day after admission. The lesion was completely improved 10 days after initiation of therapy and there were no serious problems. Discussion: Due to the ineffectiveness of antidote therapy for the management of delayed extravasation of vincristine and beneficial effect of our clinical approach, it could consider for the management of similar cases with delayed extravasation following vincristine administration.
- Open Access
- 21 April 2023
- Published byĀ Springer NatureĀ inĀ Research Square
Comparison of Global Decolonization Efficacy with Mupirocin Nasal Drop and Chlorhexidine Mouthwash in Acute Leukemia Patients: Randomized Clinical Trial
Purpose Neutropenic fever remains a major complication in acute leukemia. Decolonization is assumed as a promising intervention for eradicating causative agents of infection Methods In this randomized clinical trial, 96 patients with acute leukemia were assigned randomly to mupirocin nasal drop 2% (n = 32), chlorhexidine mouthwash 0.2% (n = 33), and control group (n = 31). In control group patients did not receive any medication for decolonization. All patients received treatment for 5 days (2 days prior to chemotherapy until 3 days after chemotherapy). Pharynx and nasal swabs were taken prior to the intervention and at the end of decolonization period in all groups. Antibiotic susceptibility testing was performed by the disc diffusion method in order to identify bacterial isolates. Results Bacterial recovery of both nasal and pharynx swabs was observed after global decolonization with mupirocin nasal drop. Decolonization with mupirocin significantly eradicated Coagulase-negative staphylococci (CONS) in both nasal and pharynx swabs (p-value = 0.000). Moreover, mupirocin decreased pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) species. Chlorhexidine mouthwash significantly eradicated CONS in pharynx swabs (p-value = 0.000). In addition, both decolonization strategies decreased both antibiotic use and frequency of fever in leukemic patients. Conclusion Global decolonization with mupirocin nasal drop not only eradicates both nasal and pharynx microorganisms, but also reduces antibiotic requirement and frequency of fever in patients with acute leukemia. The protocol of the present study was approved on December 2016 (registry number: IRCT20160310026998N6).
- 21 April 2023
- Published byĀ Springer NatureĀ inĀ Research Square
Open AccessComparison of Global Decolonization Efficacy with Mupirocin Nasal Drop and Chlorhexidine Mouthwash in Acute Leukemia Patients: Randomized Clinical Trial
Purpose Neutropenic fever remains a major complication in acute leukemia. Decolonization is assumed as a promising intervention for eradicating causative agents of infection Methods In this randomized clinical trial, 96 patients with acute leukemia were assigned randomly to mupirocin nasal drop 2% (n = 32), chlorhexidine mouthwash 0.2% (n = 33), and control group (n = 31). In control group patients did not receive any medication for decolonization. All patients received treatment for 5 days (2 days prior to chemotherapy until 3 days after chemotherapy). Pharynx and nasal swabs were taken prior to the intervention and at the end of decolonization period in all groups. Antibiotic susceptibility testing was performed by the disc diffusion method in order to identify bacterial isolates. Results Bacterial recovery of both nasal and pharynx swabs was observed after global decolonization with mupirocin nasal drop. Decolonization with mupirocin significantly eradicated Coagulase-negative staphylococci (CONS) in both nasal and pharynx swabs (p-value = 0.000). Moreover, mupirocin decreased pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) species. Chlorhexidine mouthwash significantly eradicated CONS in pharynx swabs (p-value = 0.000). In addition, both decolonization strategies decreased both antibiotic use and frequency of fever in leukemic patients. Conclusion Global decolonization with mupirocin nasal drop not only eradicates both nasal and pharynx microorganisms, but also reduces antibiotic requirement and frequency of fever in patients with acute leukemia. The protocol of the present study was approved on December 2016 (registry number: IRCT20160310026998N6).
- Open Access
- 2 July 2022
- Published byĀ Maad Rayan Publishing CompanyĀ inĀ Advanced Pharmaceutical Bulletin
- Vol.Ā 13 Ā (3) , 621-626
Long and Short-term Metformin Consumption as a Potential Therapy to Prevent Complications of COVID-19
Purpose: The aim of the study is to evaluate the effect of metformin in complication improvement of hospitalized patients with COVID-19. Methods: This was a randomized clinical trial that involved 189 patients with confirmed COVID-19 infection. Patients in the intervention group received metformin-500 mg twice daily. Patients who received metformin before admission were excluded from the control group. Patients who were discharged before taking at least 2000 mg of metformin were excluded from the study. Primary outcomes were vital signs, need for ICU admission, need for intubation, and mortality. Results: Data showed that patients with diabetes with previous metformin in their regimen had lower percentages of ICU admission and death in comparison with patients without diabetes (11.3% vs. 26.1% (P=0.014) and 4.9% vs. 23.9% (Pā¤0.001), respectively). Admission time characteristics were the same for both groups except for diabetes and hyperlipidemia, which were significantly different between the two groups. Observations of naproxen consumption on endpoints, duration of hospitalization, and the levels of spO2 did not show any significant differences between the intervention and the control group. The adjusted OR for intubation in the intervention group versus the control group was 0.21 [95% CI, 0.04-0.99 (P=0.047)]. Conclusion: In this trial, metformin consumption had no effect on mortality and ICU admission rates in non-diabetic patients. However, metformin improved COVID-19 complications in diabetic patients who had been receiving metformin prior to COVID-19 infection, and it significantly lowered the intubation rates.
- 2 July 2022
- Published byĀ Maad Rayan Publishing CompanyĀ inĀ Advanced Pharmaceutical Bulletin
- Vol.Ā 13 Ā (3) , 621-626
Open AccessLong and Short-term Metformin Consumption as a Potential Therapy to Prevent Complications of COVID-19
Purpose: The aim of the study is to evaluate the effect of metformin in complication improvement of hospitalized patients with COVID-19. Methods: This was a randomized clinical trial that involved 189 patients with confirmed COVID-19 infection. Patients in the intervention group received metformin-500 mg twice daily. Patients who received metformin before admission were excluded from the control group. Patients who were discharged before taking at least 2000 mg of metformin were excluded from the study. Primary outcomes were vital signs, need for ICU admission, need for intubation, and mortality. Results: Data showed that patients with diabetes with previous metformin in their regimen had lower percentages of ICU admission and death in comparison with patients without diabetes (11.3% vs. 26.1% (P=0.014) and 4.9% vs. 23.9% (Pā¤0.001), respectively). Admission time characteristics were the same for both groups except for diabetes and hyperlipidemia, which were significantly different between the two groups. Observations of naproxen consumption on endpoints, duration of hospitalization, and the levels of spO2 did not show any significant differences between the intervention and the control group. The adjusted OR for intubation in the intervention group versus the control group was 0.21 [95% CI, 0.04-0.99 (P=0.047)]. Conclusion: In this trial, metformin consumption had no effect on mortality and ICU admission rates in non-diabetic patients. However, metformin improved COVID-19 complications in diabetic patients who had been receiving metformin prior to COVID-19 infection, and it significantly lowered the intubation rates.
- Open Access
- 26 April 2022
- Published byĀ Springer NatureĀ inĀ Research Square
An investigation of insulin resistance and cachexia in patients with metastatic upper GI malignancies
IntroductionInsulin resistance has been suggested as one of the known metabolic disorders during cachexia. This study hypothesized that cachexia in cancer patients might be due to insulin resistance as early as cachexia development. MethodThis study was performed on 46 patients with metastatic gastrointestinal cancer. Anthropometric characteristics and biochemical markers were assessed at baseline, second month, and third month. Insulin resistance was assessed using the HOMA IR method. SFQ-36 questions were used to assess the patients' quality of life at baseline, second and third months.ResultsPatients' anthropometric characteristic was significantly associated between pre-cachectic and non-pre-cachectic patients in the third month. Cholesterol (P-value: 0.93), albumin (P-value: 0.82), and serum creatinine (P-value: 0.88) in pre-cachectic patients decreased over three months. There was an increasing trend of insulin resistance between pre-cachectic and non-pre-cachectic patients in the third month. Cholesterol had an upward trend with a significant relation in cachectic patients [(P-value: 0.00), (P-value: 0.03), (P-value: 0.01)]. We detected a decreasing trend of insulin resistance between cachectic and non-cachectic patients from the second to the third month (Pvalue= 0.04). SFQ evaluation had no significant relation with cachectic status.ConclusionSignificant relation between anthropometric variables with pre-cachexia and cachectic conditions was concluded. Patients' outcome and its relation with insulin resistance (age of 30ā¤, and above 30ā„) demonstrated a significant relation between the cachectic and non-cachectic patients in the third month. We also detected the increased serum cholesterol level in cachectic patients, moreover, higher cholesterol levels in expired cachectic patients than in the living.
- 26 April 2022
- Published byĀ Springer NatureĀ inĀ Research Square
Open AccessAn investigation of insulin resistance and cachexia in patients with metastatic upper GI malignancies
IntroductionInsulin resistance has been suggested as one of the known metabolic disorders during cachexia. This study hypothesized that cachexia in cancer patients might be due to insulin resistance as early as cachexia development. MethodThis study was performed on 46 patients with metastatic gastrointestinal cancer. Anthropometric characteristics and biochemical markers were assessed at baseline, second month, and third month. Insulin resistance was assessed using the HOMA IR method. SFQ-36 questions were used to assess the patients' quality of life at baseline, second and third months.ResultsPatients' anthropometric characteristic was significantly associated between pre-cachectic and non-pre-cachectic patients in the third month. Cholesterol (P-value: 0.93), albumin (P-value: 0.82), and serum creatinine (P-value: 0.88) in pre-cachectic patients decreased over three months. There was an increasing trend of insulin resistance between pre-cachectic and non-pre-cachectic patients in the third month. Cholesterol had an upward trend with a significant relation in cachectic patients [(P-value: 0.00), (P-value: 0.03), (P-value: 0.01)]. We detected a decreasing trend of insulin resistance between cachectic and non-cachectic patients from the second to the third month (Pvalue= 0.04). SFQ evaluation had no significant relation with cachectic status.ConclusionSignificant relation between anthropometric variables with pre-cachexia and cachectic conditions was concluded. Patients' outcome and its relation with insulin resistance (age of 30ā¤, and above 30ā„) demonstrated a significant relation between the cachectic and non-cachectic patients in the third month. We also detected the increased serum cholesterol level in cachectic patients, moreover, higher cholesterol levels in expired cachectic patients than in the living.
- 18 March 2022
- Published byĀ WileyĀ inĀ Phytotherapy Research
- Vol.Ā 36 Ā (4) , 1644-1651
Antiāhyperglycemic effect of Abelmoschus culentesus (Okra) on patients with diabetes type 2: a randomized clinical trial
Okra (Abelmoschus esculentus) has traditionally been used in diabetes treatment. This study investigated the effect of Okra whole fruit on blood glucose level of patients with diabetes mellitus type 2 with concomitant use of oral hypoglycemic agents. In this doubleāblind randomized clinical trial, 120 diabetic patients were assigned to okra group (n = 60) and control group (n = 60). The okra group received 1,000 mg of A.esculentus whole fruit capsules orally, every 6 hr for 8 weeks. The control group received placebo capsule in the same manner. The levels of FBS (fasting blood sugar), BS (blood sugar), and Hemoglobin A1C (HgA1c) were measured at baseline and after intervention in both groups. The levels of FBS, BS, and HgA1c were significantly decreased in okra group within the intervention compared to control group (p < .05). Moreover, the numbers to treat (NNT) for FBS, BS, and HgA1C were seven, eight, and seven, respectively. Okra whole fruit supplementation has a promising antiāhyperglycemic effect in patients with diabetes mellitus type 2 who received oral agents. Diabetic patients could benefit from adjuvant therapy of okra with other medication.
- 18 March 2022
- Published byĀ WileyĀ inĀ Phytotherapy Research
- Vol.Ā 36 Ā (4) , 1644-1651
Antiāhyperglycemic effect of Abelmoschus culentesus (Okra) on patients with diabetes type 2: a randomized clinical trial
Okra (Abelmoschus esculentus) has traditionally been used in diabetes treatment. This study investigated the effect of Okra whole fruit on blood glucose level of patients with diabetes mellitus type 2 with concomitant use of oral hypoglycemic agents. In this doubleāblind randomized clinical trial, 120 diabetic patients were assigned to okra group (n = 60) and control group (n = 60). The okra group received 1,000 mg of A.esculentus whole fruit capsules orally, every 6 hr for 8 weeks. The control group received placebo capsule in the same manner. The levels of FBS (fasting blood sugar), BS (blood sugar), and Hemoglobin A1C (HgA1c) were measured at baseline and after intervention in both groups. The levels of FBS, BS, and HgA1c were significantly decreased in okra group within the intervention compared to control group (p < .05). Moreover, the numbers to treat (NNT) for FBS, BS, and HgA1C were seven, eight, and seven, respectively. Okra whole fruit supplementation has a promising antiāhyperglycemic effect in patients with diabetes mellitus type 2 who received oral agents. Diabetic patients could benefit from adjuvant therapy of okra with other medication.
- Open Access
- 30 August 2021
- Published byĀ Springer NatureĀ inĀ Research Square
Prophylactic Effect of Memantine in Docetaxel Induced Neuropathy in Patients With Breast Cancer
Purpose Peripheral neuropathy is a complication of taxane that in severe cases can limit the optimal treatment. The aim of this study was to evaluate the efficacy of memantine in prevention of docetaxel induced peripheral neuropathy in patients with breast cancer. Methods In this randomized clinical trial, 40 women between the ages of 18 and 64 years with non-metastatic breast cancer (stages I to III) were included (registry number: IRCT20160310026998N9 and registry date: 26 March 2019). All patients were treated with the AC-T regimen (with docetaxel). Patients in intervention group received memantine at a dose of 20 mg for 8 weeks at the beginning of the first cycle of docetaxel. Patients in control group did not take any medication for neuropathy prevention. To assess the neuropathy, DN4 and CTCAE questionnaires were used at baseline, one months, three months and six months after the intervention. Results The DN4 questionnaire score was remarkably less in memantine group in follow up one (p-value: 0.033) and three (p < 00.1). The CTCAE follow up score did not change during study. The Neuropathy duration and Neuropathy onset, were shown significant difference between the intervention and control groups, p = 0.050 and p = 0.001, respectively. From 40 patients, 8 (40%) in memantine group and 2 (10%) in control group, did not experience any kind of neuropathy. Conclusion Data showed that prophylactic administration of memantine 20 mg/day has been effective in prevention of severity and incidence of docetaxel induced neuropathy in patients with breast cancer.
- 30 August 2021
- Published byĀ Springer NatureĀ inĀ Research Square
Open AccessProphylactic Effect of Memantine in Docetaxel Induced Neuropathy in Patients With Breast Cancer
Purpose Peripheral neuropathy is a complication of taxane that in severe cases can limit the optimal treatment. The aim of this study was to evaluate the efficacy of memantine in prevention of docetaxel induced peripheral neuropathy in patients with breast cancer. Methods In this randomized clinical trial, 40 women between the ages of 18 and 64 years with non-metastatic breast cancer (stages I to III) were included (registry number: IRCT20160310026998N9 and registry date: 26 March 2019). All patients were treated with the AC-T regimen (with docetaxel). Patients in intervention group received memantine at a dose of 20 mg for 8 weeks at the beginning of the first cycle of docetaxel. Patients in control group did not take any medication for neuropathy prevention. To assess the neuropathy, DN4 and CTCAE questionnaires were used at baseline, one months, three months and six months after the intervention. Results The DN4 questionnaire score was remarkably less in memantine group in follow up one (p-value: 0.033) and three (p < 00.1). The CTCAE follow up score did not change during study. The Neuropathy duration and Neuropathy onset, were shown significant difference between the intervention and control groups, p = 0.050 and p = 0.001, respectively. From 40 patients, 8 (40%) in memantine group and 2 (10%) in control group, did not experience any kind of neuropathy. Conclusion Data showed that prophylactic administration of memantine 20 mg/day has been effective in prevention of severity and incidence of docetaxel induced neuropathy in patients with breast cancer.
- Open Access
- 10 March 2020
- Published byĀ Maad Rayan Publishing CompanyĀ inĀ Pharmaceutical Sciences
- Vol.Ā 26 Ā (1) , 25-31
Protective Effects of Selenium in Patients with Beta-Thalassemia Major
Background : Beta-thalassemia major patients require repeated blood transfusion which is associated with iron overload in different organs such as heart, liver, kidney and their related complications. In this study the effects of selenium in iron overload related complications of patients with beta-thalassemia major were assessed. Methods: In this clinical trial, 34 beta-thalassemia major patients over 12 years old were enrolled. Patients with severe renal failure, history of selenium consumption over the last three months, change of blood transfusion pattern, and any change of chelating agent were excluded from the study. For all patients, tablet of selenium 200 µg/day was administered for a month. Blood samples were taken at baseline and after one-month to assess the level of ferritin, total iron-binding capacity (TIBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum creatinine (Scr), selenium. Hair loss was assessed by questionnaire before and after intervention. Results: From 34 patients, 27 (79.4%) had deficient level of selenium at baseline. The selenium level was increased after intervention (p=0.005). The level of serum ALT and Scr decreased remarkably after one-month selenium consumption (p=0.007 for both). In addition, the AST level decreased remarkably after intervention (p=0.053). Severe hair loss profile has improved significantly after supplementation (p=0.004). Conclusion: One-month selenium consumption improved liver and kidney function related markers remarkably. Moreover, selenium improved hair profile and severe hair loss in thalassemia patients. Further studies are needed on the effect of selenium administration on liver and kidney function.
- 10 March 2020
- Published byĀ Maad Rayan Publishing CompanyĀ inĀ Pharmaceutical Sciences
- Vol.Ā 26 Ā (1) , 25-31
Open AccessProtective Effects of Selenium in Patients with Beta-Thalassemia Major
Background : Beta-thalassemia major patients require repeated blood transfusion which is associated with iron overload in different organs such as heart, liver, kidney and their related complications. In this study the effects of selenium in iron overload related complications of patients with beta-thalassemia major were assessed. Methods: In this clinical trial, 34 beta-thalassemia major patients over 12 years old were enrolled. Patients with severe renal failure, history of selenium consumption over the last three months, change of blood transfusion pattern, and any change of chelating agent were excluded from the study. For all patients, tablet of selenium 200 µg/day was administered for a month. Blood samples were taken at baseline and after one-month to assess the level of ferritin, total iron-binding capacity (TIBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum creatinine (Scr), selenium. Hair loss was assessed by questionnaire before and after intervention. Results: From 34 patients, 27 (79.4%) had deficient level of selenium at baseline. The selenium level was increased after intervention (p=0.005). The level of serum ALT and Scr decreased remarkably after one-month selenium consumption (p=0.007 for both). In addition, the AST level decreased remarkably after intervention (p=0.053). Severe hair loss profile has improved significantly after supplementation (p=0.004). Conclusion: One-month selenium consumption improved liver and kidney function related markers remarkably. Moreover, selenium improved hair profile and severe hair loss in thalassemia patients. Further studies are needed on the effect of selenium administration on liver and kidney function.
- Open Access
- 9 January 2019
- Published byĀ BrieflandsĀ inĀ Jundishapur Journal of Natural Pharmaceutical Products
- Vol.Ā In Press Ā (In Press)
Effect of Achillea millefolium Mouthwash on Oral Mucositis Induced by Chemotherapy in AML Patients
Jundishapur Journal of Natural Pharmaceutical Products
- 9 January 2019
- Published byĀ BrieflandsĀ inĀ Jundishapur Journal of Natural Pharmaceutical Products
- Vol.Ā In Press Ā (In Press)
Open AccessEffect of Achillea millefolium Mouthwash on Oral Mucositis Induced by Chemotherapy in AML Patients
Jundishapur Journal of Natural Pharmaceutical Products